CROPIN
11.6.2019 10:27:05 CEST | Business Wire | Press release
CropIn, a full-stack agri-tech organization, has registered a 3X ARR growth over the last five quarters and has grown by 325% during the last 15 months. The SaaS provider, which first marked its global presence in late 2017, is today generating more than 60% of its current revenue from its international markets and is targeting to achieve 70% of the revenue from these markets in the next one year. CropIn has partnered with over 100+ B2B enterprise clients across 30+ countries in Asia, Europe, Africa, and the Americas, enriching the lives of over 2.1 million farmers by digitizing over 5 million acres of farmland.
A pioneer in the agri-tech space, the company's growth story started with the launch of its first product ‘SmartFarm ’. SmartFarm is a comprehensive digital farming technology that enables efficient farm management through digitization, empowers data-driven decision-making, and provides complete visibility of people, processes, and performance on the field.
‘SmartFarm ’ is a globally recognized and awarded digital platform, which was recently named the ‘Best Innovation in Digital Farming Technology’ at Agrow Awards in London. (SmartFarm case study link on HBR )
CropIn launched its predictive and prescriptive solution, ‘SmartRisk™ ’ that leverages Satellite Imagery, Artificial Intelligence and Machine Learning. SmartRisk™ is a next generation solution that can detect crops remotely, predict crop health and estimate yield ahead of the harvest, and provides valuable insights for the agri industry, financial institutions, growers and policy makers.
SmartRisk™ is capable of performing regional/plot level analysis, on a 10x10 sq mt pixel that is updated every 10 days, consolidating it at a village, postal code, district and country view. It is the perfect product for business entities such as input companies, commodity traders, farming companies, banks, and insurance companies that are seeking regional insights to make major financial and strategic decisions. CropIn has carried out swift and successful technology implementations in the agri-tech space on a global scale. The company’s other core product offerings include SmartSales, mWarehouse and Acresquare.
CropIn has raised $12 million funding till date, including Series A funding from BEENEXT, and $8 million in a Series B funding from the Bill and Melinda Gates Foundation Strategic Investment Fund (London & Seattle) and Chiratae Ventures.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005394/en/
Contact:
Team Pumpkin Roshan Ravindra roshan@teampumpkin.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
Fastly Joins DIMPACT to Collaborate on Digital Sustainability8.7.2026 14:00:00 CEST | Press release
Fastly Brings Leading Cloud Edge Expertise to Help DIMPACT Members Understand and Optimize Digital Carbon Footprints Fastly, Inc. (NASDAQ: FSLY), a leading global edge cloud platform, today announced it has become a participant of DIMPACT, the coalition of leading organizations working to align industry changemakers and policymakers around meaningful, science-based solutions that reduce the environmental impacts of serving digital media products. As the first edge cloud platform provider to join the coalition, Fastly brings critical, real-world edge network data and infrastructure expertise and a transparent approach to emissions calculation and reporting to help major media, streaming, and publishing companies understand and optimize their digital carbon footprints. “We’re thrilled to welcome Fastly to the DIMPACT initiative. Their participation strengthens DIMPACT's ability to advance a more accurate, data-driven approach to measuring and reducing digital emissions,” said Jason Bell,
PubNub Introduces Blocks.ai: The Control Plane and Network Layer For AI Agents8.7.2026 14:00:00 CEST | Press release
Connect and control agents from everywhere, across any network and device, on the Blocks Network. PubNub introduces Blocks.ai today, a global network to connect and control agents across all agent frameworks, providers, and APIs. Blocks.ai lets developers reach their existing AI agents regardless of where they are hosted. Blocks Network supports all AI agent use cases without opening inbound ports, setting up tunnels, changing DNS, or modifying firewall rules. For more than a decade, PubNub has been the infrastructure and platform for real-time connectivity supporting billions of devices, now, PubNub delivers Blocks Network connecting the Internet of Agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708521206/en/ AI agents have become increasingly critical to businesses who want control over their models, code, and data. But once those agents are running locally or behind a firewall, making them reachable from custom
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development8.7.2026 14:00:00 CEST | Press release
Partnership pairs GMP-manufactured iPSC lines with matched RUO equivalents, giving developers well-characterized, donor-eligible starting materials from early research through clinical development. Supporting comparability data for the RUO and GMP lines to be presented at the 2026 ISSCR Annual Meeting in Montréal, Canada. STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) today announced a partnership to expand access to high-quality human induced pluripotent stem cell (iPSC) starting materials, giving cell therapy developers worldwide a faster, lower-risk path from research to the clinic. Under the agreement, STEMCELL will manufacture and distribute research-use-only (RUO) iPSC lines derived directly from LineaBio's Good Manufacturing Practices (GMP) iPSC lines, and will offer the matched GMP lines to developers worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708212795/en
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom